BACKGROUND: @entity954 ( @entity954 )-guided lumpectomy in early @entity0 has shown advantages over other techniques. However, the use of @entity954 has been less explored after @entity34 ( @entity34 ). This study aimed to compare @entity954 - and wire localization (WL)-guided surgery in @entity0 @entity1 after @entity34 . METHODS: The study enrolled @entity1 treated with @entity34 who underwent breast-conserving surgery (BCS) between July 2008 and December 2012. For the @entity1 with a hydrogel marker or @entity41 visible on ultrasound, an @entity954 -guided surgery was performed ( @entity954 group). The @entity1 with a standard marker or hydrogel marker not visible on ultrasound underwent a WL-guided surgery (WL group). RESULTS: The study investigated 214 @entity1 : 145 (67.8  %) in the @entity954 group and 69 (32.2  %) in the WL group. The @entity1 and @entity5 characteristics were comparable between the two groups. For the @entity1 who had a pathologic complete response (pCR) or microscopic disease, the volume excised was lower in the @entity954 group (p  =  0.03). The rate of reexcision for positive or close margins was similar in the two groups (p  =  0.80). After a median follow-up period of 43  months, the local recurrence rates did not differ significantly between the two groups. CONCLUSIONS: Compared with WL surgery, @entity954 seems to lower the volume of resection in @entity1 with pCR or minimal microscopic disease after @entity34 without compromising margins and local recurrences. BCS can easily be achieved with @entity954 for @entity1 with a good response after @entity34 .

Intraoperative Ultrasound-Guided Lumpectomy Versus Mammographic Wire Localization for @entity0 XXXX After Neoadjuvant Treatment.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity954 :: ('MESH:D016063', 'Disease') :: ['IOUS', 'Intraoperative ultrasound'] @entity34 :: ('MESH:D016609', 'Disease') :: ['NAT', 'neoadjuvant treatment']
@entity1 :: (9606,Species) :: ['Patients']
